BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases, today announced that the editorial ???Treatment of the Heart Failure Patient with Atrial Fibrillation: A Major Unmet Need??? was published in the first edition of JACC: Heart Failure,